GLPG5101*
CD19
CAR-T
Relapsed/refractory hematological malignancies
Our Pipeline
Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of potential best-in-class therapies.
Oncology Pipeline
Hematological tumors
Candidate
Target
Class
Indication
Discovery
IND/CTA Enabling
Phase 1
Phase 2
GLPG5301
BCMA
CAR-T
Relapsed/refractory multiple myeloma
Asset 1
Armored bi-specific
CAR-T
B-cell malignancies
Asset 2
Non-disclosed
CAR-T
Multiple myeloma
Solid tumors
Candidate
Target
Class
Indication
Discovery
IND/CTA Enabling
Phase 1
Phase 2
Uza-cel¹
MAGE-A4, expressing CD8α
TCR-T
Head & neck cancer
Asset 3
Non-disclosed
CAR-T
Small-cell lung cancer and neuro-endocrine
Asset 4
Non-disclosed
CAR-T
Platinum-resistant ovarian
1Collaboration with Adaptimmune
High-risk DLBCL with International Prognostic Index 3-5 or double/triple-hit lymphoma, primary refractory disease, defined as subjects failing to achieve a complete response to first-line anti-CD20 and anthracycline-based chemoimmunotherapy after ≥2 cycles at the interim disease assessment; IND: Investigational New Drug application; CTA: Clinical Trial Application; CAR T-cell therapy: Chimeric antigen receptor T cell therapy; TCR T-cell therapy: T cell receptor T cell therapy;
* Protocol for GLPG5101 currently being amended to include DLBCL-RT and CLL. We announced on February 12, 2025, that we are focusing our resources on accelerating GLPG5101 as our flagship CD19 CAR-T program. Pending the advancement of GLPG5101 in additional indications, we are deprioritizing activities for GLPG5201, our second CD19 CAR-T candidate.
Immunology Pipeline
Candidate
Target
Class
Indication
Discovery
IND/CTA Enabling
Phase 1
Phase 2
GLPG3667
TYK2
Small molecule
SLEDM
pBIC candidate
Non-disclosed
Small molecule
Inflammatory bowel disease
pBIC assets
Multiple
Small molecule
Inflammation/auto-immune disorders
pBIC: potential Best-In-Class; SLE: Systemic lupus erythematosus; DM: Dermatomyositis
Visit our Clinical Trials Portal
Clinical trials are a critical part of our journey to evaluate investigational treatments and gain approval from health authorities such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
At Galapagos, we organize clinical trials in various therapeutic areas, conducting research that paves the way for innovative solutions.
Visit our Clinical Trials portal to explore the fascinating world of clinical trials. Discover how they’re set up and gain insight into what’s important when considering participation.
Our stories
More about our company, science and people
We curate a series of inspiring stories about how we are #LivingInnovation at Galapagos
Partnerships
Work with us!
We are adding new capabilities, technologies and product candidates through internal and external innovation. Let’s start #PioneeringForPatients, together!
Investor Hub
All information for investors…
… centralized in one Investor Hub. Discover how we aim to create value for all our stakeholders.